Experimental drug may delay development of type 1 diabetes

  • Experimental drug may delay development of type 1 diabetes

Experimental drug may delay development of type 1 diabetes

She said: "In Milton Keynes there are 13,971 people who have been diagnosed and are living with diabetes, and it is thought that more than half of all cases of Type 2 diabetes could be prevented or delayed with the early identification of people at risk of developing it in the future".

The drug was well tolerated and the safety data were consistent with prior studies in newly diagnosed patients.

The groundbreaking study "demonstrates that we can use immunotherapy, specifically PRV-031, to prevent or significantly delay the onset of clinical type 1 diabetes by at least two years in individuals who will nearly certainly progress to clinical disease", said Dr. Eleanor Ramos, Provention's chief medical officer and chief operating officer.

The first year after teplizumab therapy yielded the largest benefit for patients, reducing the risk for developing type 1 diabetes by 87% compared with the saline placebo (unadjusted HR 0.13, 95% CI 0.05-0.34).

An investigative therapy has shown capability to delay type 1 diabetes (T1D) progression in patients at high risk of the chronic autoimmune disease. All participants were tracked to see if they developed Type 1 diabetes over the next few years. "As anyone with Type 1 diabetes will tell you, every day you can delay this disease is important". "In addition, we look forward to learning more as we observe patients during the study's follow-up period, which will also evaluate the long-term outcomes for those in whom the diagnosis of disease has been delayed to see if they will be diagnosed with T1D or are protected". Not having diabetes for two years, seven years, or even one year is a big deal. "We will not waver in our mission to eradicate type 1 diabetes".

Then, last spring, New Jersey-based Provention Bio reached a deal with MacroGenics to acquire the rights to the drug, betting on its potential to halt immune attacks on beta levels.

The TrialNet research has been funded by the US National Institutes of Health (NIH), primarily through the Special Diabetes Program, with additional support from JDRF.

The study involved 76 participants aged between 8-49 years deemed to be at high risk of the condition. Those given the drug developed the autoimmune disease in an average of 48 months. A webcast replay of the call will be available beginning at 11:00 AM ET on the day of the call.

Patients' immune systems attack the cells in the pancreas that make insulin, a hormone that regulates blood sugar levels. The candidate has been the subject of multiple clinical studies involving more than 1,000 subjects with more than 800 patients receiving PRV-031 in those studies.

Diabetes occurs when our bodies fail to convert glucose into energy. Various factors such as age have contributed to the ability of the teplizumab to delay its clinical disease. In total, 19 (43%) teplizumab and 23 (72%) placebo patients were diagnosed with T1D.

According to the developer of the drug Provention Bio Inc, it is necessary to conduct additional, more extensive studies before registering teplizumab as a drug.

Commenting on the findings, Dr Clifford Rosen, who is from the Maine Medical Center Research Institute together with journal deputy editor Dr Julie Ingelfinger said: "We can finally say that there has been substantial progress in modulating the early course of type 1 diabetes". Provention's diversified portfolio includes advanced-stage product development candidates that have undergone clinical testing by other companies.